Singapore, April 10 -- Takeda and CSL Behring, a provider of plasma-derived and recombinant therapies based in King of Prussia, PA, on 6 April 2020 announced a partnership to develop a potential plasma-derived therapy to treat COVID-19 with the following companies:

Biotest: a provider of plasma proteins and biological drugs based in Dreieich, Germany.

Bio Products Laboratory: a UK-based supplier of plasma-derived treatments

LFB: a biopharmaceutical group based in France that develops, manufactures, and markets plasma-derived products and recombinant proteins

Octapharma: a human protein manufacturer headquartered in Lachen, Switzerland.

The companies will develop an investigational, unbranded anti-SARS-CoV-2 polyclonal hyperimmune imm...